Conference Archive
Advertisement
Advertisement
Trending on Modern Retina
1
First patient dosed in phase I/II trial of complement-targeting gene therapy for geographic atrophy
2
OLN324 shows comparable vision gains, potential durability advantage vs faricimab in phase 1b wAMD, DME study
3
Merck launches phase 2b/3 MALBEC trial of MK-8748 in wet AMD
4
FDA approves extended dosing intervals up to 20 weeks for EYLEA HD in wAMD and DME
5